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P-04.120 Evaluation of personality traits in depression and in
remission
M. Serra1, V. Navarro2, R. Catalán2, R. Penadés2, C. Gastó2. 1Hospital General
de Vic, Psychiatry, Spain; 2Hospital Clı́nic Barcelona, Inst. of Neurosciences,
Spain
Objective: The purpose of the present study was to evaluate the effects of
depression symptoms on personality traits.
Methods: Eighteen patients who met DSM-IV-TR criteria for unipolar major
depression were enrolled in this 24-weed prospective study. All patients were
classified as endogenous with the Newscatle Scale showing scores up to 6
points. Patients were evaluated at baseline and after 4, 8, 12, 16, 20 and
24 weeks using Hamilton Scale for Depression (HAM-D). They were also
evaluated with Eysenck Personality Questionnaire (EPQ) at baseline and after 24
weeks. The HAM-D at baseline was up to 18 pounts. All patients were treated
with escitalopram at required doses, except one patient who was treated with
nortriptiline owing to side-effects. The mean of escitalopram dose was 27 mg/day.
Results: HAM-D significantly improved from baseline to endpoint (24.1 to
3.4, p< 0.0001). Items of Neuroticism showed a significant difference from
baseline to endpoint (17.94 to 13.61, p = 0.028). Extraversion also showed a
significant difference (9.2 to 10, p = 0.048). Additionally, patients with recurrent
depression showed significant higher levels of neuroticism at baseline that
patients with a first episode of depression (20.20 to 14.62, p = 0.035). There
was not significant difference at the endpoint. Extraversion scores did not show
differences between patients with one or more episodes at baseline or endpoint.
Conclusion: Overall, depression symptomatology increased neuroticism and
decreased extraversion. Levels of neuroticism in current depression were higher
than levels at first episodes.
P-04.121 Quality of life and social functioning in depressed patients
M. Serra1, R. Penadés2, R. Catalán2, V. Navarro2, C. Gastó2. 1Hospital General
de Vic, Psychiatry, Spain; 2Hospital Clı́nic Barcelona, Inst. of Neurosciences,
Spain
Objective: The aim of this study was to assess quality of life, social functioning
and residual symptoms in a sample of unipolar major depression patients.
Methods: 58 patients who met DSM-IV-TR criteria for unipolar major
depression were evaluated (30 without psychotic symptoms and 28 patients
with psychotic symptoms). All patients were considered to show an endogenous
depression with the Newscatle Scale score up to 6 pounts. One year follow-
up was performed. Patients were treated naturalistically, and they did not
present relapses during the last six months. All patients were evaluated with
the SADS-Life (Schedule for Affective Disorders and Schizophrenia), Hamilton
Depression Rating Scale (HDRS), social functioning (SASS), quality of life
(QLDS), perceived stress (PSS) and Eysenck Personality Questionnaire (EPQ).
Results: Symptoms of depression measured with HDRS correlated negatively
with items about quality of life (Pearson’s correlations of −0.739, p< 0.0001)
and social functioning (−0.505, p< 0.0001) and positively with perceived stress
(0.748, p< 0.0001). Those correlationships were significant even when corrected
for neuroticim and extraversion. Moreover, there were not differences between
the number of past episodes and the overall functioning and residual symptoms,
indicating that residual symptoms should be independent of the number of past
episodes. Neuroticism correlated with perceived stress and quality of life but not
with social adaptation, and this correlation were significant when for depression
symptoms were controlled.
Conclusion: Presence of residual symptoms is correlated with worse quality
of life, worse social functioning and more level of stress. Residual symptoms did
not show correlationship with the number of previous episodes. After controlling
personality traits these correlations were still significant.
P-04.122 Improvement in functioning and quality of life measures
in patients with major depressive disorder treated with
desvenlafaxine
C. Soares1, M. Thase2, S.G. Kornstein3, C. Brisard4, L. Septien-Velez4,
J.-M. Germain4, B. Pitrosky4, A. Patroneva5, Q. Jiang5, P.T. Ninan5. 1McMaster
University, Psychiatry, Hamilton, ON, Canada; 2UPMC, Psychiatry, Pittsburgh,
USA; 3Virginia Commonwealth University, Psychiatry, Richmond, USA; 4Wyeth
Research, Paris, France; 5Wyeth Research, Collegeville, USA
Objective: To evaluate outcomes related to functioning and well being with
desvenlafaxine (administered as desvenlafaxine succinate) in patients with major
depressive disorder (MDD).
Methods: Data from the Sheehan Disability Scale (SDS) and 5-item World
Health Organization Well-Being Index (WHO-5) were pooled from 4 double-
blind, placebo-controlled, 8-week desvenlafaxine clinical trials (ie, all fixed-dose
trials that evaluated these outcomes) in outpatients with DSM-IV MDD. Patients
were randomized to fixed doses of desvenlafaxine (50, 100, 200, or 400 mg/d:
n = 1205) or placebo (n = 551). Final on-therapy data were compared between
groups using analysis of covariance; adjusted mean differences (desvenlafaxine
vs placebo) are presented here.
Results: Desvenlafaxine was associated with significantly greater improve-
ment versus placebo in the SDS total score in the pooled data set (−2.8;
P< 0.001) and in the 50-mg (−2.6; P< 0.001), 100-mg (−2.6; P< 0.001),
200-mg (−2.7; P< 0.001), and 400-mg (−3.2; P< 0.001) dose groups. Signif-
icant improvement (P< 0.01) in each of the 4 SDS domains compared with
placebo (work, social life/leisure activities, family life/home responsibilities,
and work/social disability) was also found for the pooled data set and each
of the individual dose groups. For the WHO-5 total score, desvenlafaxine was
associated with significantly greater improvement versus placebo in the pooled
data set (2.0; P< 0.001) and in the in the 50-mg (1.7; P< 0.001), 100-mg (2.0;
P< 0.001), 200-mg (2.3; P< 0.001), and 400-mg (2.4; P< 0.001) dose groups.
Significant improvement (P< 0.05) compared with placebo was also found for
the pooled data set and the individual dose groups for each of the WHO-5
individual items (good spirits, calm/relaxed, active/vigorous, fresh/rested, and
interested in activities).
Conclusion: Desvenlafaxine effectively improved functioning and well being
in patients with MDD across a wide range of doses, including the low dose
50 mg.
Research supported by Wyeth Research.
P-04.123 Increased suicide risk in depressed patients predicted by
long-chain fatty acids
N. Solowij1, B. Grenyer1, B. Meyer2, P. Howe3. 1University of Wollongong,
School of Psychology, Wollongong, NSW, Australia; 2University of Wollongong,
School of Health Sciences, Wollongong, NSW, Australia; 3University of South
Australia, School of Health Sciences, Adelaide SA, Australia
Objective: A relationship between omega-3 fatty acid intake and depression
is suggested by data from epidemiological cross-national comparisons of fish
consumption and case control studies. A significant risk factor from depression is
suicide, and population studies in Finland and Japan have established that suicide
risk decreases with increased fish consumption. In China, patients admitted to
hospital for a suicide attempt were found to have significantly lower n-3 fatty
acid levels compared to matched controls, with this depletion conferring an eight
fold increased risk of suicide. Follow-up studies report omega-3s predict suicide
attempts. There are few studies of clinically depressed patients’ suicide risk with
respect to fatty acid status. This study aimed to assess the relationship between
suicide risk and fatty acid levels in clinically depressed patients.
Methods: 60 treatment seeking outpatients suffering a current episode of
DSM-IV diagnosed major depression were studied. Half the patients had no
suicidal ideas, whereas the other half (N = 31) had current suicidal attempts,
gestures and/or ideation assessed by a trained psychodiagnostician and measures
from the Hamilton Rating Scale for Depression. Fatty acids in red blood cell
membranes were analysed and compared between groups.
Results: The overall model found that total n-3 and n-6 fatty acid levels
predicted 14% of the variance in suicidal intentions. Further analysis found
that Docosapentaenoic Acid (DPA) 22:5n-3 levels predicted severity of suici-
dal intentions (r = −0.26, p = 0.04). Lower levels of DPA and total very long
chain omega-6 (VLCn6) fatty acids differentiated groups (F= 3.80, p = 0.05
and F = 4.89, p = 0.03, respectively). Data from clinical interview was cross-
validated against patient self-report using the Beck Depression Inventory-Suicide
item. Lower VLCn6 levels also predicted higher self-reported suicidal ideation
(r = −0.25, p = 0.04). Unlike some other studies, lower cholesterol did not predict
increased suicide risk.
Conclusion: Low polyunsaturated long-chain fatty acid levels in red blood
cell membranes confer a higher risk of suicidal ideation, gestures, and attempts
in clinically depressed outpatients. Further study of the clinical significance of
these findings is warranted.
P-04.124 Major depression and suicidal ideation in cancer patients
V. Sushko. Odessa State Medical University, Dept. of Psychiatry, Ukraine
Objective: Major depression is frequently observed, however, it is underesti-
mated in cancer patients. Major depression is a major risk factor for suicide and
for requests to hasten death in cancer patients. Suicidal ideation should prompt
a comprehensive evaluation. The purpose of this study was to develop a simple
battery for screening major depression and suicidal ideation in cancer patients.
The aim of this study was to investigate the prevalence of and factors associated
with major depression in cancer patients.
